Institutional's are buying because Lazard Capital Market reported yesterday very good data from Ponatinib frontline therapy of PH+ ALL, the data will be presented at the ASCO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.